Receptor tyrosine Kinase-Mediated angiogenesis

Cold Spring Harbor Perspectives in Medicine

Volumn 3, Issue 9, 2013, Pages

  Jeltsch, Michael ^a   Leppänen, Veli Matti ^a   Saharinen, Pipsa ^a   Alitalo, Kari ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; LIGAND; TIE RECEPTOR; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ARTICLE; BIOLOGICAL MODEL; EMBRYO DEVELOPMENT; ENDOTHELIUM CELL; ENZYMOLOGY; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; PHYSIOLOGY;

ANGIOGENESIS INHIBITORS; EMBRYONIC DEVELOPMENT; ENDOTHELIAL CELLS; LIGANDS; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTORS, TIE; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 84883759753     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a009183     Document Type: Article

References (205)

1. Abdullah SE, Perez-Soler R. 2011. Mechanisms of resistance to vascular endothelial growth factor blockade. Cancer 118: 3455-3467.
2. Achen MG, Stacker SA. 2008. Molecular control of lymphatic metastasis. Ann NYAcad Sci 1131: 225-234.
3. Adams RH, Eichmann A. 2010. Axon guidance molecules in vascular patterning. Cold Spring Harb Perspect Biol 2: a001875.
4. Albuquerque RJC, Hayashi T, Cho WG, Kleinman ME, Dridi S, Takeda A, Baffi JZ, Yamada K, Kaneko H, Green MG, et al. 2009. Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. NatMed 15:1023-1030.
5. Alders M, Hogan BM, Gjini E, Salehi F, Al-Gazali L, Henne-kam EA, Holmberg EE, Mannens MM, Mulder MF, Offerhaus GJ, et al. 2009. Mutations in CCBE1 cause generalized lymph vessel dysplasia in humans. Nat Genet 41: 1272-1274.
6. Alitalo K. 2011. The lymphatic vasculature in disease. Nat Med 17: 1371-1380.
7. Andrae J, Gallini R, Betsholtz C. 2008. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 22: 1276-1312.
8. Anisimov A, Alitalo A, Korpisalo P, Soronen J, Kaijalainen S, Leppänen V-M, Jeltsch M, Ylä-Herttuala S, Alitalo K. 2009. Activated forms of VEGF-C and VEGF-D provide improved vascular function in skeletal muscle. Circ Res 104: 1302-1312.
9. Anisimov A, Tvorogov D, Alitalo A, Leppanen VM, An Y, Han EC, Orsenigo F, Gaal El, Holopainen T, Koh YJ, et al. 2013. Vascular endothelial growth factor-angiopoietin chimera with improved properties for therapeutic angiogenesis. Circulation 127: 424-434.
10. Augustin HG. 2005. Angiogenesis in the female reproductive system. EXS 94: 35-52.
11. Augustin HG, Koh GY, Thurston G, Alitalo K. 2009. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 10: 165-177.
12. Baeriswyl V, Christofori G. 2009. The angiogenic switch in carcinogenesis. Semin Cancer Biol 19: 329-337.
13. Baffert F, Le T, Thurston G, McDonald DM. 2006. Angio-poietin-1 decreases plasma leakage by reducing number and size of endothelial gaps in venules. AmJPhysiol Heart CircPhysiol 290: H107-H118.
14. Bais C, Wu X, Yao J, Yang S, Crawford Y, McCutcheon K, Tan C, Kolumam G, Vernes JM, Eastham-Anderson J, et al. 2010. P1GF blockade does not inhibit angiogenesis during primary tumor growth. Cell 141: 166-177.
15. Baldwin ME, Catimel B, Nice EC, Roufail S, Hall NE, Stenvers KL, Karkkainen MJ, Alitalo K, Stacker SA, Achen MG. 2001. The specificity of receptor binding by vascular endothelial growth factor-D is different in mouse and man. J Biol Chem 276: 19166-19171.
16. Baldwin ME, Halford MM, Roufail S, Williams RA, Hibbs ML, Grail D, Kubo H, Stacker SA, Achen MG. 2005. Vascular endothelial growth factor D is dispensable for development of the lymphatic system. Mol Cell Biol 25: 2441-2449.
17. Barton WA, Tzvefkova-Robev D, Miranda EP, Kolev MV, Rajashankar KR, Himanen JP, Nikolov DB. 2006. Crystal structures of the Tie2 receptor ectodomain and the an-giopoietin-2-Tie2 complex. Nat Struct Mol Biol 13: 524-532.
18. Bellomo D, Headrick JP, Silins GU, Paterson CA, Thomas PS, Gartside M, Mould A, Cahill MM, Tonks ID, Grim-mond SM, et al. 2000. Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia. Circ Res 86: E29-E35.
19. Bhargava P, Robinson MO. 2011. Development of second-generation VEGFR tyrosine kinase inhibitors: Current status. Curr Oncol Rep 13: 103-111.
20. Bollinger A, Isenring G, Franzeck UK, Brunner U. 1983. Aplasia of superficial lymphatic capillaries in hereditary and connatal lymphedema (Milro/s disease). Lymphol-ogy 16: 27-30.
21. Bos FL, Caunt M, Peterson-Maduro J, Planas-Paz L, Kowal-ski J, Karpanen T, van Impel A, Tong R, Ernst JA, Korving I, et al. 2011. CCBE1 is essential for mammalian lymphatic vascular development and enhances the lymphangiogenie effect of vascular endothelial growth factor-C in vivo. Circ Res 109: 486-491.
22. Boulpaep EL. 2009. Arteries and veins The microcirculation. Medical physiology: A cellular and molecular approach (ed. Boron WF, Boulpaep EL), pp. 467-503. Saunders Elsevier, Philadelphia.
23. Bremnes RM, Camps C, Sirera R. 2006. Angiogenesis in non-small cell lung cancer: The prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer 51: 143-158.
24. Brouillard P, Vikkula M. 2007. Genetic causes of vascular malformations. Hum Mol Genet 16 (Spec No. 2): R140-R149.
25. Brown JL, Cao ZA, Pinzon-Ortiz M, Kendrew J, Reimer C, Wen S, Zhou JQ, Tabrizi M, Emery S, McDermott B, et al. 2010. A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models. Mol Cancer Ther 9: 145-156.
26. Bry M, Kivelä R, Holopainen T, Anisimov A, Tammela T, Soronen J, Silvola J, Saraste A, Jeltsch M, Korpisalo P, et al. 2010. Vascular endothelial growth factor-B acts as a coronary growth factor in transgenic rats without inducing angiogenesis, vascular leak, or inflammation. Circulation 122: 1725-1733.
27. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, et al. 1996. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380: 435-439.
28. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M, Wu Y, Bono F, Devy L, Beck H, et al. 2001. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 7: 575-583.
29. Cascone I, Napione L, Maniero F, Serini G, Bussolino E 2005. Stable interaction between α5β;l integrin and Tie2 tyrosine kinase receptor regulates endothelial cell response to Ang-1. JCell Biol 170: 993-1004.
30. Caunt M, Mak J, Liang W-C, Stawicki S, Pan Q, Tong RK, Kowalski J, Ho C, Reslan HB, Ross J, et al. 2008. Blocking neuropilin-2 function inhibits tumor cell metastasis. Cancer Cell 13: 331-342.
31. Chae S-S, Kamoun WS, Farrar CT, Kirkpatrick ND, Niemey-er E, de Graaf AMA, Sorensen AG, Munn LL, Jain RK, Fukumura D. 2010. Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas. Clin Cancer Res 16: 3618-3627.
32. Chappell JC, Taylor SM, Ferrara N, Bautch VL. 2009. Local guidance of emerging vessel sprouts requires soluble Flt-1. Dev Cell 17: 377-386.
33. Costa C, Incio Jo, Soares R. 2007. Angiogenesis and chronic inflammation: Cause or consequence? Angiogenesis 10: 149-166.
34. Coxon A, Bready J, Min H, Kaufman S, Leal J, Yu D, Lee TA, Sun JR, Estrada J, Bolon B, et al. 2010. Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: Implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody Mol Cancer Ther 9: 2641-2651.
35. Daly C, Eichten A, Castanaro C, Pasnikowski E, Adler A, Lalani AS, Papadopoulos N, Kyle AH, Minchinton AI, Yancopoulos GD, et al. 2013. Angiopoietin-2 functions as a tie2 agonist in tumor models, where it limits the effects ofVEGF inhibition. Cancer Res 73: 108-118.
36. D'Amico G, Korhonen EA, Waltari M, Saharinen P, Laakko-nen P, Alitalo K. 2010. Loss of endothelial Tiel receptor impairs lymphatic vessel development-brief report. Arte-rioscler Thromb VascBiol 30: 207-209.
37. David S, Mukherjee A, Ghosh CC, Yano M, Khankin EV, Wenger JB, Karumanchi SA, Shapiro NI, Parikh SM. 2012. Angiopoietin-2 may contribute to multiple organ dysfunction and death in sepsis. Crit Care Med 40: 3034-3041.
38. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Iain V, Ryan TE, Bruno J, Radziejewski C, Maisonpierre PC, et al. 1996. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 87: 1161-1169.
39. Dellinger M, Hunter R, Bernas M, Gale N, Yancopoulos G, Erickson R, Witte M. 2008. Defective remodeling and maturation of the lymphatic vasculature in Angiopoietin-2 deficient mice. Dev Biol 319: 309-320.
40. del Toro R, Prahst C, Mathivet T, Siegfried G, Kaminker JS, Larrivee B, Breant C, Duarte A, Takakura N, Fukamizu A, et al. 2010. Identification and functional analysis of endothelial tip cell-enriched genes. Blood 116: 4025-4033.
41. De Luca A, Normanno N. 2010. Tivozanib, a pan-VEGFR tyrosine kinase inhibitor for the potential treatment of solid tumors. IDrugs 13: 636-645.
42. Dumont DJ, Gradwohl G, Fong GH, Puri MC, Gertsenstein M, Auerbach A, Breitman ML. 1994. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev 8: 1897-1909.
43. Dumont DJ, Jussila L, Taipale J, Lymboussaki A, Mustonen T, Pajusola K, Breitman M, Alitalo K. 1998. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science 282: 946-949.
44. Ebos JML, Lee CR, Cruz-Munoz W, Bjarnason GA, Chris-tensen JG, Kerbel RS. 2009. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15: 232-239.
45. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, et al. 2007. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125-134.
46. Falcon BL, Hashizume H, Koumoutsakos P, Chou J, Bready JV, Coxon A, Oliner JD, McDonald DM. 2009. Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels. AmJPathol 175: 2159-2170.
47. Fantin A, Vieira JM, Gestri G, Denti L, Schwarz Q, Prykhoz-hij S, Peri F, Wilson SW, Ruhrberg C. 2010. Tissue mac-rophages act as cellular chaperones for vascular anastomosis downstream of VEGF-mediated endothelial tip cell induction. Blood 116: 829-840.
48. Favier B, Alam A, Barron P, Bonnin J, Laboudie P, Fons P, Mandron M, Herault J-P, Neufeld G, Savi P, et al. 2006. Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migration. Blood 108: 1243-1250.
49. Felcht M, Luck R, Schering A, Seidel P, Srivastava K, Hu J, Bartol A, Kienast Y, Vettel C, Loos EK, et al. 2012. Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling. J Clin Invest 122: 1991-2005.
50. Ferrara N. 2004. Vascular endothelial growth factor: Basic science and clinical progress. EndocrRev 25: 581-611.
51. Ferrara N. 2010. Role of myeloid cells in vascular endothelial growth factor-independent tumor angiogenesis. Curr Opin Hematol 17: 219-224.
52. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, Powell-Braxton L, Hillan KJ, Moore MW. 1996. Heterozygous embryonic lethality induced by targeted inac-tivation of the VEGF gene. Nature 380: 439-442.
53. Ferrara N, Hillan KJ, Novotny W. 2005. Bevacizumab (Avas-tin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 333: 328-335.
54. Ferrara N, Mass RD, Campa C, Kim R. 2007. Targeting VEGF-A to treat cancer and age-related macular degeneration. Annu Rev Med 58: 491-504.
55. Fiedler U, Scharpfenecker M, Koidl S, Hegen A, Grunow V, Schmidt JM, Kriz W, Thurston G, Augustin HG. 2004. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood 103: 4150-4156.
56. Fiedler U, Reiss Y, Scharpfenecker M, Grunow V, Koidl S, Thurston G, Gale NW, Witzenrath M, Rosseau S, Suttorp N, et al. 2006. Angiopoietin-2 sensitizes endothelial cells to TNF-a and has a crucial role in the induction of inflammation. Nat Med 12: 235-239.
57. Fong GH, Rossant J, Gertsenstein M, Breitman ML. 1995. Role of the Fit-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376: 66-70.
58. Fong GH, Zhang L, Bryce DM, Peng J. 1999. Increased he-mangioblast commitment, not vascular disorganization, is the primary defect in fit-1 knock-out mice. Development 126: 3015-3025.
59. Fukuhara S, Sako K, Minami T, Noda K, Kim HZ, Kodama T, Shibuya M, Takakura N, Koh GY, Mochizuki N. 2008. Differential function of Tie2 at cell-cell contacts and cell-substratum contacts regulated by angiopoietin-1. Nat Cell Biol 10: 513-526.
60. Fuller T, Korff T, Kilian A, Dandekar G, Augustin HG. 2003. Forward EphB4 signaling in endothelial cells controls cellular repulsion and segregation from ephrinB2 positive cells. JCellSci 116: 2461-2470.
61. Gale NW, Thurston G, Hackett SF, Renard R, Wang Q, McClain J, Martin C, Witte C, Witte MH, Jackson D, et al. 2002. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell 3: 411-423.
62. Galvagni F, Pennacchini S, Salameh A, Rocchigiani M, Neri F, Orlandini M, Petraglia F, Gotta S, Sardone GL, Mat-teucci G, et al. 2010. Endothelial cell adhesion to the extracellular matrix induces c-Src-dependent VEGFR-3 phosphorylation without the activation of the receptor intrinsic kinase activity. CircRes 106: 1839-1848.
63. Gerber HP, Kowalski J, Sherman D, Eberhard DA, Ferrara N. 2000. Complete inhibition of rhabdomyosarcoma xeno-graft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res 60: 6253-6258.
64. Gerhardt H, Ruhrberg C, Abramsson A, Fujisawa H, Shima D, Betsholtz C. 2004. Neuropilin-1 is required for endothelial tip cell guidance in the developing central nervous system. Dev Dyn 231: 503-509.
65. Germain S, Monnot C, Muller L, Eichmann A. 2010. Hy-poxia-driven angiogenesis: Role of tip cells and extracellular matrix scaffolding. Curr Opin Hematol 17: 245-251.
66. Goede V, Coutelle O, Neuneier J, Reinacher-Schick A, Schnell R, Koslowsky TC, Weihrauch MR, Cremer B, Kashkar H, Odenthal M, et al. 2010. Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizu-mab-containing therapy. Br J Cancer 103: 1407-1414.
67. Gordon K, Schulte D, Brice G, Simpson MA, Roukens MG, van Impel A, Connell F, Kalidas K, Jeffery S, Mortimer PS, et al. 2013. Mutation in vascular endothelial growth fac-tor-C, a ligand for vascular endothelial growth factor receptor-3, is associated with autosomal dominant mil-roy-like primary lymphedema. CircRes 112: 956-960.
68. Goyal S, Chauhan SK, Dana R. 2012. Blockade of prolym-phangiogenic vascular endothelial growth factor C in dry eye disease. Arch Ophthalmol 130: 84-89.
69. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ. 1996. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379: 88-91.
70. Hagerling R, Pollmann C, Andreas M, Schmidt C, Nurmi H, Adams RH, Alitalo K, Andresen V, Schulte-Merker S, Kiefer F. 2013. A novel multistep mechanism for initial lymphangiogenesis in mouse embryos based on ultrami-croscopy. EMBO J 32: 629-644.
71. Haiko P, Makinen T, Keskitalo S, Taipale J, Karkkainen MJ, Baldwin ME, Stacker SA, Achen MG, Alitalo K. 2008. Deletion of vascular endothelial growth factor C (VEGF-C) and VEGF-D is not equivalent to VEGF receptor 3 deletion in mouse embryos. Mol Cell Biol 28: 4843-4850.
72. Hammes H-P, Lin J, Wagner P, Feng Y, Vom Hagen F, Krzizok T, Renner O, Breier G, Brownlee M, Deutsch U. 2004. Angiopoietin-2 causes pericyte dropout in the normal retina: Evidence for involvement in diabetic retinopafhy. Diabetes 53: 1104-1110.
73. Hanahan D, Christofori G, Naik P, Arbeit J. 1996. Transgenic mouse models of tumour angiogenesis: The angiogenic switch, its molecular controls, and prospects for preclin-ical therapeutic models. Eur J Cancer 32A: 2386-2393.
74. Hashizume H, Falcon BL, Kuroda T, Baluk P, Coxon A, Yu D, Bready JV, Oliner JD, McDonald DM. 2010. Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res 70: 2213-2223.
75. He Y, Kozaki K-I, Karpanen T, Koshikawa K, Yla-Herttuala S, Takahashi T, Alitalo K. 2002. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. JNatl CancerInst9i: 819-825.
76. He Y, Rajantie I, Ilmonen M, Makinen T, Karkkainen MJ, Haiko P, Salven P, Alitalo K. 2004. Preexisting lymphatic endothelium but not endothelial progenitor cells are essential for tumor lymphangiogenesis and lymphatic metastasis. Cancer Res 64: 3737-3740.
77. He Y, Rajantie I, Pajusola K, Jeltsch M, Holopainen T, Yla-Herttuala S, Harding T, Jooss K, Takahashi T, Alitalo K. 2005. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res 65: 4739-4746.
78. Hiratsuka S, Minowa O, Kuno J, Noda T, Shibuya M. 1998. Fit-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci 95: 9349-9354.
79. Ho VC, Duan LJ, Cronin C, Liang BT, Fong GH. 2012. Elevated vascular endothelial growth factor receptor-2 abundance contributes to increased angiogenesis in vascular endothelial growth factor receptor-1-deficient mice. Circulation 126: 741-752.
80. Hogan BM, Bos FL, Bussmann J, Witte M, Chi NC, Duckers H J, Schulte-Merker S. 2009. Ccbe 1 is required for embryonic lymphangiogenesis and venous sprouting. Nat Ge-net 41: 396-398.
81. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, Yancopoulos GD, Wiegand SJ. 1999. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284: 1994-1998.
82. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, et al. 2002. VEGF-Trap: AVEGF blocker with potent antitumor effects. Proc Natl Acad Sci 99: 11393-11398.
83. Holopainen T, Saharinen P, DAmico G, Lampinen A, Eklund L, Sormunen R, Anisimov A, Zarkada G, Lohela M, Helotera H, et al. 2012. Effects of angiopoietin-2-blocking antibody on endothelial cell-cell junctions and lung metastasis. J Natl Cancer Inst 104: 461-475.
84. Huang J, Bae J-O, Tsai JP, Kadenhe-Chiweshe A, Papa J, Lee A, Zeng S, Kornfeld ZN, Ullner P, Zaghloul N, et al. 2009. Angiopoietin-l/Tie-2 activation contributes to vascular survival and tumor growth during VEGF blockade. IntJ Oncol 34: 79-87.
85. Huang H, Lai J-Y, Do J, Liu D, Li L, Del Rosario J, Doppa-lapudi VR, Pirie-Shepherd S, Levin N, Bradshaw C, et al. 2011. Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth. Clin Cancer Res 17: 1001-1011.
86. Hudkins RL, Becknell NC, Zulli AL, Underiner TL, Angeles TS, Aimone LD, Albom MS, Chang H, Miknyoczki SJ, Hunter K, et al. 2012. Synthesis and biological profile of the pan-vascular endothelial growth factor recep-tor/tyrosine kinase with immunoglobulin and epidermal growth factor-like homology domains 2 (VEGF-R/ TIE-2) inhibitor ll-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a] pyrrolo[3,4-c]carbazol-4-one (CEP-11981): A novel oncology therapeutic agent. J Med Chem 55: 903-913.
87. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, et al. 2004. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. NEnglJMed 350: 2335-2342.
88. Hwang J-A, Lee EH, Kim H-W, Park JB, Jeon BH, Cho C-H. 2009. COMP-Angl potentiates the antitumor activity of 5-fluorouracil by improving tissue perfusion in murine Lewis lung carcinoma. Mol Cancer Res 7: 1920-1927.
89. Hyde CA, Giese A, Stuttfeld E, Abram Saliba J, Villemagne D, Schleier T, Binz HK, Ballmer-Hofer K. 2012. Targeting extracellular domains D4 and D7 of vascular endothelial growth factor receptor 2 reveals allosteric receptor regulatory sites. Mol Cell Biol 32: 3802-3813.
90. Iain RK. 2005. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307:58-62.
91. Jakobsson L, Bentley K, Gerhardt H. 2009. VEGFRs and Notch: A dynamic collaboration in vascular patterning. Biochem Soc Trans 37: 1233-1236.
92. lanse AJ, van Coevorden F, Peterse H, Keus RB, van Dongen JA. 1995. Lymphedema-induced lymphangiosarcoma. EurJSurg Oncol 21: 155-158.
93. Jeansson M, Gawlik A, Anderson G, Li C, Kerjaschki D, Henkelman M, Quaggin SE. 2011. Angiopoietin-1 is essential in mouse vasculature during development and in response to injury. J Clin Invest 121: 2278-2289.
94. Jeltsch M, Tammela T, Alitalo K, Wilting J. 2003. Genesis and pathogenesis of lymphatic vessels. Cell Tissue Res 314:69-84.
95. Joukov V, Sorsa T, Kumar V, Jeltsch M, Claesson-Welsh L, Cao Y, Saksela O, Kalkkinen N, Alitalo K. 1997. Proteo-lytic processing regulates receptor specificity and activity of VEGF-C. EMBOJ 16: 3898-3911.
96. Kaipainen A, Korhonen J, Mustonen T, van Hinsbergh VW, Fang GH, Dumont D, Breitman M, Alitalo K. 1995. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. ProcNatlAcad Sci 92: 3566-3570.
97. Karkkainen MJ, Ferrell RE, Lawrence EC, Kimak MA, Lev-inson KL, McTigue MA, Alitalo K, Finegold DN. 2000. Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. Nat Genet 25: 153-159.
98. Karkkainen MJ, Saaristo A, Jussila L, Karila KA, Lawrence EC, Pajusola K, Bueler H, Eichmann A, Kauppinen R, Kettunen MI, et al. 2001. A model for gene therapy of human hereditary lymphedema. Proc Natl Acad Sci 98: 12677-12682.
99. Karkkainen MJ, Haiko P, Sainio K, Partanen J, Taipale J, Petrova TV, Jeltsch M, Jackson DG, Talikka M, Rauvala H, et al. 2004. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol 5: 74-80.
100. Karlan BY, Oza AM, Richardson GE, Provencher DM, Han-sen VL, Buck M, Chambers SK, Ghatage P, Pippitt CH Jr, Brown JV III, et al. 2012. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol 30: 362-371.
101. Karpanen T, Egeblad M, Karkkainen MJ, Kubo H, Ylä-Hert-tuala S, Jäättelä M, Alitalo K. 2001. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res 61: 1786-1790.
102. Karpanen T, Wirzenius M, Mäkinen T, Veikkola T, Haisma HJ, Achen MG, Stacker SA, Pytowski B, Ylä-Herttuala S, Alitalo K. 2006. Lymphangiogenic growth factor responsiveness is modulated by postnatal lymphatic vessel maturation. AmJPathol 169: 708-718.
103. Kearney JB, Ambler CA, Monaco KA, Johnson N, Rapoport RG, Bautch VL. 2002. Vascular endothelial growth factor receptor Fit-1 negatively regulates developmental blood vessel formation by modulating endothelial cell division. Blood 99: 2397-2407.
104. Kendall RL, Thomas KA. 1993. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci 90: 10705-10709.
105. Kendrew J, Eberlein C, Hedberg B, McDaid K, Smith NR, Weir HM, Wedge SR, Blakey DC, Foltz I, Zhou J, et al. 2011. An antibody targeted to VEGFR-2 Ig domains 4-7 inhibits VEGFR-2 activation and VEGFR-2-dependent angiogenesis without affecting ligand binding. Mol Cancer Ther 10: 770-783.
106. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N. 1993. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362: 841-844.
107. Kim I, Kwak HJ, Ahn JE, So JN, Liu M, Koh KN, Koh GY 1999. Molecular cloning and characterization of a novel angiopoietin family protein, angiopoietin-3. FEBS Lett 443: 353-356.
108. Kim KT, Choi HH, Steinmetz MO, Maco B, Kammerer RA, Ahn SY, Kim HZ, Lee GM, Koh GY. 2005. Oligomeriza-tion and multimerization are critical for angiopoietin-1 to bind and phosphorylate Tie2. JBiol Chem 280:20126-20131.
109. Kim HA, Mahato RI, Lee M. 2009. Hypoxia-specific gene expression for ischemic disease gene therapy. Adv Drug DelivRev 61: 614-622.
110. Kleinman ME, Greives MR, Churgin SS, Blechman KM, Chang El, Ceradini DJ, Tepper OM, Gurtner GC. 2007. Hypoxia-induced mediators of stem/progenitor cell trafficking are increased in children with hemangioma. Arte-rioscler Thromb Vase Biol 27: 2664-2670.
111. Koch S, Tugues S, Li X, Gualandi L, Claesson-Welsh L. 2011. Signal transduction by vascular endothelial growth factor receptors. Biochem J 437: 169-183.
112. Koh YJ, Kim H-Z, Hwang S-I, Lee JE, Oh N, Jung K, Kim M, Kim KE, Kim H, Lim N-K, et al. 2010. Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoie-tins in tumor angiogenesis, metastasis, and vascular leakage. Cancer Cell 18: 171-184.
113. Lacorre D-A, Baekkevold ES, Garrido I, Brandtzaeg P, Har-aldsen G, Amalric Fo, Girard J-R 2004. Plasticity of endothelial cells: Rapid dedifferentiation of freshly isolated high endothelial venule endothelial cells outside the lym-phoid tissue microenvironment. Blood 103: 4164-4172.
114. Lee HJ, Cho C-H, Hwang S-J, Choi H-H, Kim K-T, Ahn SY, Kim J-H, Oh J-L, Lee GM, Koh GY 2004. Biological characterization of angiopoietin-3 and angiopoietin-4. FASEB J 18: 1200-1208.
115. Leow CC, Coffman K, Inigo I, Breen S, Czapiga M, Souk-harev S, Gingles N, Peterson N, Fazenbaker C, Woods R, et al. 2012. MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models. Int J Oncol 40: 1321-1330.
116. Leppanen VM, Jeltsch M, Anisimov A, Tvorogov D, Aho K, Kalkkinen N, Toivanen P, Yla-Herttuala S, Ballmer-Hofer K, Alitalo K. 2011. Structural determinants of vascular endothelial growth factor-D receptor binding and specificity. Blood 117: 1507-1515.
117. Li X, Stankovic M, Bonder CS, Hahn CN, Parsons M, Pitson SM, Xia P, Proia RL, Vadas MA, Gamble JR. 2008a. Basal and angiopoietin-1-mediated endothelial permeability is regulated by sphingosine kinase-1. Blood 111: 3489-3497.
118. Li X, Tjwa M, Van Hove I, Enholm B, Neven E, Paavonen K, Jeltsch M, Juan TD, Sievers RE, Chorianopoulos E, et al. 2008b. Reevaluation of the role of VEGF-B suggests a restricted role in the revascularization of the ischemic myocardium. Arterioscler Thromb Vase Biol 28: 1614-1620.
119. Limaye N, Wouters V, Uebelhoer M, Tuominen M, Wirkkala R, Mulliken JB, Eklund L, Boon LM, Vikkula M. 2009. Somatic mutations in angiopoietin receptor gene TEK cause solitary and multiple sporadic venous malformations. Nat Genet 41: 118-124.
120. Lin P, Buxton JA, Acheson A, Radziejewski C, Maisonpierre PC, Yancopoulos GD, Channon KM, Hale LP, Dewhirst MW, George SE, et al. 1998. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine ki-nase Tie2. Proc NatlAcad Sci 95: 8829-8834.
121. Lin J, Lalani AS, Harding TC, Gonzalez M, Wu W-W, Luan B, Tu GH, Koprivnikar K, VanRoey MJ, He Y, et al. 2005. Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res 65: 6901-6909.
122. Lindsay CR, MacPherson IR, Cassidy J. 2009. Current status of cediranib: The rapid development of a novel anti-an-giogenic therapy. Future Oncol 5: 421-432.
123. Liu R, Li X, Tulpule A, Zhou Y, Scehnet JS, Zhang S, Lee JS, Chaudhary PM, Jung J, Gill PS. 2010. KSHV-induced notch components render endothelial and mural cell characteristics and cell survival. Blood 115: 887-895.
124. Losordo DW, Vale PR, Hendel RC, Milliken CE, Fortuin FD, Cummings N, Schatz RA, Asahara T, Isner JM, Kuntz RE. 2002. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 105: 2012-2018.
125. Lu D, Shen J, Vil MD, Zhang H, Jimenez X, Bohlen P, Witte L, Zhu Z. 2003. Tailoring in vitro selection for a picomo-lar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity. J Biol Chem 278: 43496-43507.
126. Lugus JJ, Park C, Choi K. 2005. Developmental relationship between hematopoietic and endothelial cells. Immunol Res 32: 57-74.
127. Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherrer A, Liao F, Nagy JA, Hooper A, Priller J, De Klerck B, et al. 2002. Revascularization of ischemic tissues by P1GF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Fit 1. NafMed 8 831-840.
128. Macdonald PR, Progias P, Ciani B, Patel S, Mayer U, Stein-metz MO, Kammerer RA. 2006. Structure of the extracellular domain of Tie receptor tyrosine kinases and localization of the angiopoietin-binding epitope. J Biol Chem 281: 28408-28414.
129. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, et al. 1997. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277: 55-60.
130. Makinen T, Jussila L, Veikkola T, Karpanen T, Kettunen MI, Pulkkanen KJ, Kauppinen R, Jackson DG, Kubo H, Ni-shikawa S, et al. 2001. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. NatMed 7: 199-205.
131. Mazzieri R, Pucci F, Moi D, Zonari E, Ranghetti A, Berti A, Politi LS, Centner B, Brown JL, Naldini L, et al. 2011. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 19: 512-526.
132. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukow-ski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, et al. 2007. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. NEnglJMed 356: 115-124.
133. Nasarre P, Thomas M, Kruse K, Helfrich I, Wolter V, Dep-permann C, Schadendorf D, Thurston G, Fiedler U, Augustin HG. 2009. Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth. Cancer Res 69: 1324-1333.
134. Ng EW, Shima DT, Calias P, Cunningham ET Jr, Guyer DR, Adamis AR 2006. Pegaptanib, a targeted anti-VEGF ap-tamer for ocular vascular disease. Nat Rev Drug Discov 5: 123-132.
135. Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, Gibson A, Sy J, Rundle AC, Hopkins JJ, et al. 2012. Ranibizumab for diabetic macular edema: Results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 119: 789-801.
136. Nilsson I, Bahram F, Li X, Gualandi L, Koch S, Jarvius M, Soderberg O, Anisimov A, Kholova I, Pytowski B, et al. 2010. VEGF receptor 2/-3 heterodimers detected in situ by proximity ligation on angiogenic sprouts. EMBOJ29: 1377-1388.
137. Nissen LJ, Cao R, Hedlund E-M, Wang Z, Zhao X, Wetter-skog D, Funa K, Brakenhielm E, Cao Y 2007. Angiogenic factors FGF2 and PDGF-BB synergistically promote mu-rine tumor neovascularization and metastasis. J Clin Invest 117:2766-2777.
138. Norrmén C, Tammela T, Petrova TV, Alitalo K. 2011. Biological basis of therapeutic lymphangiogenesis. Circulation 123: 1335-1351.
139. North PE, Waner M, Buckmiller L, James CA, Mihm MCJ. 2006. Vascular tumors of infancy and childhood: Beyond capillary hemangioma. Cardiovasc Pathol 15: 303-317.
140. Ny A, Koch M, Schneider M, Neven E, Tong RT, Maity S, Fischer C, Plaisance S, Lambrechts D, Heligon C, et al. 2005. A genetic Xenopus laevis tadpole model to study lymphangiogenesis. Nat Med 11: 998-1004.
141. Olsson A-K, Dimberg A, Kreuger J, Claesson-Welsh L. 2006. VEGF receptor signaling-in control of vascular function. Nat Rev Mol Cell Biol 7: 359-371.
142. Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, Casanovas O. 2009. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15: 220-231.
143. Pan Q, Chanthery Y, Liang W-C, Stawicki S, Mak J, Rathore N, Tong RK, Kowalski J, Yee SF, Pacheco G, et al. 2007. Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell 11:53-67.
144. Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, Pyles EA, Yancopoulos GD, Stahl N, Wiegand SJ. 2012. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 15: 171 185.
145. Papoutsi M, Tomarev SI, Eichmann A, Prols F, Christ B, Wilting J. 2001. Endogenous origin of the lymphatics in the avian chorioallantoic membrane. Dev Dyn 222: 238-251.
146. Parikh SM, Mammoto T, Schultz A, Yuan HT, Christiani D, Karumanchi SA, Sukhatme VR 2006. Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS Med 3: e46.
147. Partanen J, Armstrong E, Mäkelä TP, Korhonen J, Sandberg M, Renkonen R, Knuutila S, Huebner K, Alitalo K. 1992. A novel endothelial cell surface receptor tyrosine kinase with extracellular epidermal growth factor homology domains. Mol CellBiol 12: 1698-1707.
148. Partanen J, Puri MC, Schwartz L, Fischer KD, Bernstein A, Rossant J. 1996. Cell autonomous functions of the receptor tyrosine kinase TIE in a late phase of angiogenic capillary growth and endothelial cell survival during mu-rine development. Development 122: 3013-3021.
149. Partanen TA, Arola J, Saaristo A, Jussila L, Ora A, Miettinen M, Stacker SA, Achen MG, Alitalo K. 2000. VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues. FASEBJ 14: 2087-2096.
150. Persaud K, Tille J-C, Liu M, Zhu Z, Jimenez X, Pereira DS, Miao H-Q, Brennan LA, Witte L, Pepper MS, et al. 2004. Involvement of the VEGF receptor 3 in tubular morphogenesis demonstrated with a human anti-human VEGFR-3 monoclonal antibody that antagonizes receptor activation by VEGF-C. J Cell Sci 117: 2745-2756.
151. Pietila R, Natynki M, Tammela T, Kangas J, Pulkki KH, Limaye N, Vikkula M, Koh GY, Saharinen P, Alitalo K, et al. 2012. Ligand oligomerization state controls Tie2 receptor trafficking and angiopoietin-2-specific responses. J Cell Sci 125: 2212-2223.
152. Pipp F, Heil M, Issbrucker K, Ziegelhoeffer T, Martin S, van den Heuvel J, Weich H, Fernandez B, Golomb G, Carme-liet P, et al. 2003. VEGFR-1-selective VEGF homologue P1GF is arteriogenic: Evidence for a monocyte-mediated mechanism. CircRes 92: 378-385.
153. Prior BM, Yang HT, Terjung RL. 2004. What makes vessels grow with exercise training? J Appl Physiol 97: 1119-1128.
154. Przewratil Pa, Sifkiewicz A, Andrzejewska E. 2010. Local serum levels of vascular endothelial growth factor in infantile hemangioma: Intriguing mechanism of endothelial growth. Cytokine 49: 141-147.
155. Puri MC, Rossant J, Alitalo K, Bernstein A, Partanen J. 1995. The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells. EMBO J 14: 5884-5891.
156. Puri MC, Partanen J, Rossant J, Bernstein A. 1999. Interaction of the TEK and TIE receptor tyrosine kinases during cardiovascular development. Development 126: 4569-4580.
157. Qu X, Tompkins K, Batts LE, Puri M, Baldwin S. 2010. Abnormal embryonic lymphatic vessel development in Tiel hypomorphic mice. Development 137: 1285-1295.
158. Quinn TP, Peters KG, De Vries C, Ferrara N, Williams IT. 1993. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc NatlAcad Sci 90: 7533-7537.
159. Reilly JP, Grise MA, Fortuin FD, Vale PR, Schaer GL, Lopez J, VAN Camp JR, Henry T, Richenbacher WE, Losordo DW, et al. 2005. Long-term (2-year) clinical events following transthoracic intramyocardial gene transfer of VEGF-2 in no-option patients. JInterv Cardiol 18: 27-31.
160. Reiss Y, Knedla A, Tal AO, Schmidt MHH, Jugold M, Kies-sling F, Burger AM, Wolburg H, Deutsch U, Plate KH. 2009. Switching of vascular phenotypes within a murine breast cancer model induced by angiopoietin-2. J Pathol 217:571-580.
161. Roberts N, Kloos B, Cassella M, Podgrabinska S, Persaud K, Wu Y, Pytowski B, Skobe M. 2006. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than in-activation of VEGFR-2. Cancer Res 66: 2650-2657.
162. Rosenfeld PJ, Rich RM, Lalwani GA. 2006. Ranibizumab: Phase III clinical trial results. Ophthalmol Clin North Am 19: 361-372.
163. Ruhrberg C, Gerhardt H, Golding M, Watson R, Ioannidou S, Fujisawa H, Betsholtz C, Shima DT 2002. Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes Dev 16: 2684-2698.
164. Saharinen P, Kerkelä K, Ekman N, Marron M, Brindle N, Lee GM, Augustin H, Koh GY, Alitalo K. 2005. Multiple an-giopoietin recombinant proteins activate the Tiel receptor tyrosine kinase and promote its interaction with Tie2 J Cell Biol 169: 239-243.
165. Saharinen P, Eklund L, Miettinen J, Wirkkala R, Anisimov A, Winderlich M, Nottebaum A, Vestweber D, Deutsch U, Koh GY, et al. 2008. Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts. Nat Cell Biol 10: 527-537.
166. Saharinen P, Eklund L, Pulkki K, Bono P, Alitalo K. 2011. VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol Med 17: 347-362.
167. Sarraf-Yazdi S, Mi J, Moeller BJ, Niu X, White RR, Kontos CD, Sullenger BA, Dewhirst MW, Clary BM. 2008. Inhibition of in vivo tumor angiogenesis and growth via systemic delivery of an angiopoietin 2-specific RNA ap-tamer./Surg Res 146: 16-23.
168. Sato TN, Tozawa Y, Deutsch U, Wolburg-Buchholz K, Fuji-wara Y, Gendron-Maguire M, Gridley T, Wolburg H, Ri-sau W, Qin Y 1995. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 376: 70-74.
169. Seegar TC, Eller B, Tzvetkova-Robev D, Kolev MV, Henderson SC, Nikolov DB, Barton WA. 2010. Tiel -Tie2 interactions mediate functional differences between angiopoietin ligands. Mol Cell 37: 643-655.
170. Sennino B, McDonald DM. 2012. Controlling escape from angiogenesis inhibitors. Nat Rev Cancer 12: 699-709.
171. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, Schuh AC. 1995. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376: 62-66.
172. Shibuya M, Claesson-Welsh L. 2006. Signal transduction by VEGF receptors in regulation of angiogenesis and lym-phangiogenesis. Exp Cell Res 312: 549-560.
173. Singh M, Ferrara N. 2012. Modeling and predicting clinical efficacy for drugs targeting the tumor milieu. Nat Bio-technol 30: 648-657.
174. Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schoffski P, Collin F, Pandite L, Marreaud S, De Brauwer A, et al. 2009. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: A phase II study from the European organization for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). JClin Oncolll: 3126-3132.
175. Snuderl M, Batista A, Kirkpatrick ND, Ruiz de Almodovar C, Riedemann L, Walsh EC, Anolik R, Huang Y, Martin ID, Kamoun W, et al. 2013. Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell 152: 1065-1076.
176. Stacker SA, Stenvers K, Caesar C, Vitali A, Domagala T, Nice E, Roufail S, Simpson RJ, Moritz R, Karpanen T, et al. 1999. Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers. J Biol Chem 274: 32127-32136.
177. Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K. 2002. Lymphangiogenesis and cancer metastasis. Nat Rev Cancer 2: 573-583.
178. Stewart DJ, Kutryk MJB, Fitchett D, Freeman M, Camack N, Su Y, Delia Siega A, Bilodeau L, Burton JR, Proulx G, et al. 2009. VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: Results of the NORTHERN trial. Mol Ther 17: 1109-1115.
179. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN, Yancopoulos GD. 1996. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87: 1171-1180.
180. Tabruyn SP, Colton K, Morisada T, Fuxe J, Wiegand SJ, Thurston G, Coyle AJ, Connor J, McDonald DM. 2010. Angiopoietin-2-driven vascular remodeling in airway inflammation. Am 1 Pathol 177: 3233-3243.
181. Tammela T, Alitalo K. 2010. Lymphangiogenesis: Molecular mechanisms and future promise. Cell 140: 460-476.
182. Tammela T, Saaristo A, Holopainen T, Lyytikkä J, Kotronen A, Pitkonen M, Abo-Ramadan U, Ylä-Herttuala S, Pet-rova TV, Alitalo K. 2007. Therapeutic differentiation and maturation of lymphatic vessels after lymph node dissection and transplantation. NatMed 13: 1458-1466.
183. Tammela T, Zarkada G, Wallgard E, Murtomaki A, Such ting S, Wirzenius M, Waltari M, Hellstrom M, Schomber T, Peltonen R, et al. 2008. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 454: 656-660.
184. Tammela T, Saaristo A, Holopainen T, Ylä-Herttuala S, An-dersson LC, Virolainen S, Immonen I, Alitalo K. 2011a. Photodynamic ablation of lymphatic vessels and intralymphatic cancer cells prevents metastasis. Sci Transl Med 3:69.
185. Tammela T, Zarkada G, Nurmi H, Jakobsson L, Heinolainen K, Tvorogov D, Zheng W, Franco CA, Murtomaki A, Aranda E, et al. 2011b. VEGFR-3 controls tip to stalk conversion at vessel fusion sites by reinforcing Notch signalling. Nat Cell Biol 13: 1202-1213.
186. Teng LS, Jin KT, He KF, Zhang J, Wang HH, Cao J. 2010. Clinical applications of VEGF-trap (aflibercept) in cancer treatment. J Chin Med Assoc 73: 449-456.
187. Thomas M, Felcht M, Kruse K, Kretschmer S, Deppermann C, Biesdorf A, Rohr K, Benest AV, Fiedler U, Augustin HG 2010. Angiopoietin-2 stimulation of endothelial cells induces avfS3 integrin internalization and degradation. J Biol Chem 285: 23842-23849.
188. Tonnesen MG, Feng X, Clark RA. 2000. Angiogenesis in wound healing. J Investig Dermatol Symp Proc 5: 40-46.
189. Tvorogov D, Anisimov A, Zheng W, Leppänen V-M, Tammela T, Laurinavicius S, Holnthoner W, Heloterä H, Holopainen T, Jeltsch M, et al. 2010. Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dime-rization. Cancer Cell 18: 630-640.
190. Valenzuela DM, Griffiths JA, Rojas J, Aldrich TH, Jones PF, Zhou H, McClain J, Copeland NG, Gilbert DJ, Jenkins NA, et al. 1999. Angiopoietins 3 and 4: Diverging gene counterparts in mice and humans. Proc Natl Acad Sci 96: 1904-1909.
191. Van de Veire S, Stalmans I, Heindryckx F, Oura H, Tijeras-Raballand A, Schmidt T, Loges S, Albrecht I, Jonckx B, Vinckier S, et al. 2010. Further pharmacological and genetic evidence for the efficacy of P1GF inhibition in cancer and eye disease. Cell 141: 178-190.
192. Van Meter ME, Kim ES. 2010. Bevacizumab: Current updates in treatment. Curr Opin Oncol 22: 586-591.
193. Vikkula M, Boon LM, Carraway KLr, Calvert JT, Diamonti AJ, Goumnerov B, Pasyk KA, Marchuk DA, Warman ML, Cantley LC, et al. 1996. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinaseTIE2. Cell87: 1181-1190.
194. Virgili G, Parravano M, Menchini F, Brunetti M. 2012. Anti-angiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. Cochrane Database SystRev 12: CD007419.
195. Vuorio T, Jauhiainen S, Yla-Herttuala S. 2012. Pro- and anti-angiogenic therapy and atherosclerosis with special emphasis on vascular endothelial growth factors. Exp Opin Biol Ther 12: 79-92.
196. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH. 1994. Different signal transduction properties of KDR and Fltl, two receptors for vascular endothelial growth factor. J Biol Chem 269: 26988-26995.
197. Weidner N, Semple JP, Welch WR, Folkman J. 1991. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324: 1-8.
198. Wigle JT, Oliver G. 1999. Proxl function is required for the development of the murine lymphatic system. Cell 98: 769-778.
199. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavt-sev I, Xu L, Hicklin DJ, Fukumura D, di Tomaso E, et al. 2004. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metal-loproteinases. Cancer Cell 6: 553-563.
200. Xu Y, Yuan L, Mak J, Pardanaud L, Caunt M, Kasman I, Larrivée B, Del Toro R, Suchting S, Medvinsky A, et al. 2010. Neuropilin-2 mediates VEGF-C-induced lymphatic sprouting together with VEGFR3. J Cell Biol 188:115-130.
201. Yano K, Brown LF, Detmar M. 2001. Control of hair growth and follicle size by VEGF-mediated angiogenesis. J Clin Invest 107: 409-417.
202. Ylä-Herttuala S. 2009. Gene therapy with vascular endothe-lial growth factors. Biochem Soc Trans 37: 1198-1200.
203. Yu L, Liang XH, Ferrara N. 2011. Comparing protein VEGF inhibitors: In vitro biological studies. Biochem Biophys Res Commun 408: 276-281.
204. Zachary I, Morgan RD. 2011. Therapeutic angiogenesis for cardiovascular disease: Biological context, challenges, prospects. Heart 97: 181-189.
205. Zhang X, Groopman JE, Wang JF. 2005. Extracellular matrix regulates endothelial functions through interaction of VEGFR-SandintegrinaSpi. J Cell Phyrsiol 202:205-214.